Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)
Sponsored by Aura Biosciences
About this trial
Last updated 2 years ago
Study ID
AU-011-402
Status
Terminated
Type
Observational
Placebo
No
Accepting
18+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 2 years ago
What is this trial about?
This is a prospective multicenter, group-matched study of patients with primary indeterminate
lesions or choroidal melanoma who receive treatment with belzupacap sarotalocan (bel-sar;
AU-011) and patients who are planned to receive standard of care (SOC) treatment with plaque
radiotherapy (plaque) to compare the visual outcomes of AU-011 and plaque radiotherapy.
What are the Participation Requirements?
Have per the investigator's expert clinical judgment, a clinical diagnosis of primary
indeterminate lesion or choroidal melanoma based on the clinical history, ophthalmic
examination, fundus photography and conventional ocular ultrasound.